The company has done fairly well & will be expanding its module mfg capacities from 450 MW to 1.2 GW & backward integrating by doing capex in Al-Frame.
🧵A Thread 🧵
The company has 17+ years of experience in solar PV mfg industry.
Current capacity is 450MW - most of the sales are derived from domestic markets.
Alpex is led by promoters with cumulative experience of 80+ years.
Aditya Sehgal (2nd generation) is director (global sales).
6 Dossiers filed for OTF, 5 MA were received on dossiers.
5.3 Cr (8% of operating revenue) was spent on R&D.
Capex of 18.1 Cr during Q1 on new warehouse, manufacturing facilities etc.
Operational Updates :
- Marketing partnership in AU & NZ markets.
- Successful Audit by NSF.
- Received 30.6 Cr (Gross) from Escrow account sale - to be deployed for Debt Reduction & Investments.
- Focusing on MENA region through partners.
FY23 PAT 13.25 Cr on 48.76 Cr Sales ~ 27% Net Margin👌
FY23 EBITDA 19.33 Cr ~ 39.6% Operating Margins
Trading at 17x EV/EBITDA & 24.6x FY23 EPS
D - No reco. ; studying about it currently
Balance Sheet :
Debt reduction : 19.3 Cr in FY22 to 4 Cr in FY23
Net-worth has increased from 18.6 Cr to 41.2 Cr
Fixed asset addition of 3 Cr during FY23 ; CWIP of 7.52 Cr
Cash Flows :
Net cash flow from operations at 16.29 Cr
Capex of 9.85 Cr during FY23 ~ FCF of 6.44 Cr
Debt repayment of 15.34 Cr during FY23
A very under-researched but very impressive Small Cap Pharma Company
R&D spend : 26Cr (FY23) ; 84 Cr in last 4 years
PAT : 24 Cr (FY23) ; 49 Cr in last 4 years (cumulative)
🧵A Thread 🧵
Current business : 77% from Pharma & 23% from Nutraceuticals
NIP (New Innovative Products) : 2 products filed in the EU; 8 products under development for developed markets; 4 developed market filings planned in FY24
- 10 NIPs in various stages of development
- Rs 62 Cr invested in gross block over last 4 years
- 44 products received registration during FY23
- 5 Marketing Authorisations received on ZIM’s Dossiers in EU in FY23